All News

Officials with the FDA have approved Allergan’s supplemental biologics application (sBLA) for onabotulinumtoxinA (Botox) for the treatment of children, ages 2 to 17 years, with upper limb spasticity.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The goal, according to agency officials, is to ensure product approval and removal decisions are science-based and that the agency’s benefit-risk framework considers not only the outcomes of prescription opioids when used as prescribed, but also the public health effects of inappropriate use.

According to the CDC, approximately 1 of 3 patients with type 1 and 2 diabetes mellitus (DM) has CKD. What do we need to know about patients with DM and CKD?

2019 Pharmacy Quality Alliance Annual Meeting included discussions on measures to improve medication services and how pharmacists can play a larger role in the multidisciplinary care team.

Top news of the day from across the health care landscape.

Investigators find visuals more effective than language when prompting people to self-screen for melanoma.

African Americans can frequently experience barriers in seeking out lifesaving clinical trials for cancer treatments.

The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.

Top news of the day from across the health care landscape.

Actress Jessica Biel’s public comments place her on an ever-growing list of famous people whose opinions are contributing to a resurgence of preventable diseases.

Pembrolizumab is already an established treatment option for non-small cell lung cancer, with several approved indications for its use in the disease.

Pembrolizumab (Keytruda, Merck) is indicated for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least 1 prior line of therapy.

Top news of the day from across the health care landscape.

A new study finds that artificial intelligence diagnoses rare diseases quicker and with more accuracy.

Baloxavir marboxil (Xofluza, Genentech) is a first in class antiviral flu treatment and is indicated in the United States for patients age 12 years and older who have been symptomatic for no more than 48 hours.

Liraglutide is the first noninsulin drug approved to treat T2D in pediatric patients since metformin was approved for pediatric use in 2000, according to the FDA.

Dr. Michael Kosal takes a data-driven and analytical approach to managing pharmacy operations. In this interview with Lynn Paterini, PharmD, host of The Nontraditional Pharmacist, see what is involved in pharmacy administration, where workdays are never the same.

Officials with the FDA today approved liraglutide (Victoza, Novo Nordisk) injection for treatment of pediatric patients age 10 years or older with type 2 diabetes (T2D).

Why does this patient have a fever, but no signs of an infection?

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

Study results demonstrate superior efficacy and comparable safety for tildrakizumab versus a placebo in patients with psoriatic arthritis.

Top news of the day from across the health care landscape.

Dogs were previously the leading cause of rabies deaths in the United States, but now bats are considered the major threat.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Officials with the FDA approved Amgen’s trastuzumab-anns, also known as ABP 980 (Kanjinti), the fifth FDA-approved biosimilar referencing trastuzumab (Herceptin).